| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/12/2010 | US7645754 Pyrrolopyrimidine A2B selective antagonist compounds, their synthesis and use |
| 01/12/2010 | US7645741 IAP BIR domain binding compounds |
| 01/12/2010 | US7645601 Isolated PGE synthase, provided from encoding nucleic acid. Methods of production and use. Assays for modulators, especially inhibitors, of PGE synthase activity. |
| 01/12/2010 | US7645449 Sensitizing cells for apoptosis by selectively blocking cytokines |
| 01/12/2010 | US7645441 Compositions and methods in cancer associated with altered expression of PRLR |
| 01/12/2010 | CA2511242C Inhibitors of human tumor-expressed ccxckr2 |
| 01/12/2010 | CA2468412C 17.alpha.-alkyl-17.beta.-oxy-estratrienes and intermediates for their production, use of the 17.alpha.-alkyl-17.beta.-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations |
| 01/12/2010 | CA2438143C Modified proteins, designer toxins, and methods of making thereof |
| 01/12/2010 | CA2427467C Sn-38 lipid complexes and methods of use |
| 01/12/2010 | CA2409664C Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione |
| 01/12/2010 | CA2407463C N-substituted peptidyl nitriles as cysteine cathepsin inhibitors |
| 01/12/2010 | CA2403514C 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors |
| 01/12/2010 | CA2398405C Chromatographic separation method of paclitaxel and cephalomannin |
| 01/12/2010 | CA2387675C Novel hydronaphtalene compounds, prepared by a rhodium catalyzed ring opening reaction in the presence of phosphine ligand |
| 01/12/2010 | CA2375834C Process for making taxane derivatives |
| 01/12/2010 | CA2368653C Z-styryl sulfone anticancer agents |
| 01/12/2010 | CA2346170C Site-specific labeling of disulfide-containing targeting vectors |
| 01/07/2010 | WO2010003057A2 Treating cancer |
| 01/07/2010 | WO2010003025A1 Bicyclic heterocycles as mek kinase inhibitors |
| 01/07/2010 | WO2010003022A1 Isoindolone derivatives as mek kinase inhibitors and methods of use |
| 01/07/2010 | WO2010003009A2 Synergistic induction of humoral and cellular immunity by combinatorial activation of toll-like receptors |
| 01/07/2010 | WO2010002983A2 Composition and methods for eliciting an immune response |
| 01/07/2010 | WO2010002970A2 Isolation of cyclopamine |
| 01/07/2010 | WO2010002956A2 Heterocyclic derivatives as modulators of ion channels |
| 01/07/2010 | WO2010002954A1 (2-aryl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)morpholine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| 01/07/2010 | WO2010002911A2 Methods and materials for monitoring myeloma using quantitative mass spetrometry |
| 01/07/2010 | WO2010002862A2 Fibroblast growth factor receptor 3 (fgfr3) binding proteins |
| 01/07/2010 | WO2010002845A2 Quinazoline derivatives |
| 01/07/2010 | WO2010002822A1 Anti-gd2 antibodies and methods and uses related thereto |
| 01/07/2010 | WO2010002779A2 Naphthyridininones as aurora kinase inhibitors |
| 01/07/2010 | WO2010002465A2 Methods for treating neoplasia by inhibiting lactate dehydrogenase and/or nicotinamide phosphoribosyltransferase |
| 01/07/2010 | WO2010002010A1 Novel spirochromanone carboxylic acids |
| 01/07/2010 | WO2010001990A1 Tetracyclic compound |
| 01/07/2010 | WO2010001989A1 Agent for reducing cancer stem cell and/or cancer progenitor cell, and agent for preventing recurrence and/or metastasis of cancer |
| 01/07/2010 | WO2010001933A1 Histone modification inhibitor specific to target gene |
| 01/07/2010 | WO2010001908A1 Anti-cd27 antibody |
| 01/07/2010 | WO2010001869A1 Tetra-substituted benzene compound and use thereof |
| 01/07/2010 | WO2010001617A1 Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human pd-1 antibody on cancers |
| 01/07/2010 | WO2010001599A1 METHOD FOR SIMULTANEOUS INDUCTION OF CTL AND γδT CELL |
| 01/07/2010 | WO2010001585A1 Anti-cdh3 antibodies labeled with radioisotope label and uses thereof |
| 01/07/2010 | WO2010001366A1 Piperazines derivatives as proteasome modulators |
| 01/07/2010 | WO2010001365A1 Nitrogen heterocycle derivatives as proteasome modulators |
| 01/07/2010 | WO2010001258A2 Inhibition of tumour growth and metastases |
| 01/07/2010 | WO2010001119A2 Use |
| 01/07/2010 | WO2010001102A2 Method |
| 01/07/2010 | WO2010000978A1 Novel pyrrolo [2,3-a] carbazoles and use thereof as pim kinase inhibitors |
| 01/07/2010 | WO2010000901A1 Antiangiogenic agents |
| 01/07/2010 | WO2010000851A2 Methods for modulating angiogenesis via dystrophin dp71 |
| 01/07/2010 | WO2010000817A1 Antitumoral macrolides |
| 01/07/2010 | WO2010000793A1 Ferrocene derivatives having antineoplastic activity |
| 01/07/2010 | WO2010000748A1 5-phenyl-isoxazole-3-carboxamides modulating hsp90 with antitumoral activities |
| 01/07/2010 | WO2010000364A1 Pyrrolopyridinylpyrimidin-2-ylamine derivatives |
| 01/07/2010 | WO2010000066A1 Diglycidic ether derivative therapeutics and methods for their use |
| 01/07/2010 | WO2010000041A1 Anti- p2x7 peptides and epitopes |
| 01/07/2010 | WO2010000025A1 Anti-pamp therapeutic antibodies |
| 01/07/2010 | WO2010000008A1 Thiosemicarbazone compounds and use thereof |
| 01/07/2010 | WO2009143024A3 Compounds and methods for kinase modulation, and indications therefor |
| 01/07/2010 | WO2009137660A9 Enhancement of drug therapy by mirna |
| 01/07/2010 | WO2009131687A3 Inhibitors of protein kinases |
| 01/07/2010 | WO2009129259A3 Polymorphs of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide and methods of use therefor |
| 01/07/2010 | WO2009126805A3 Therapeutic tarageting of mmps in neutral liposomes |
| 01/07/2010 | WO2009120899A3 G coupled protein receptors associated with myelogenous haematological proliferative disorders and uses thereof |
| 01/07/2010 | WO2009120815A9 Therapeutic compositions and methods |
| 01/07/2010 | WO2009118712A3 Novel dihydroxypyrrolidine derivatives as anti-cancer agents |
| 01/07/2010 | WO2009007536A8 Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics |
| 01/07/2010 | US20100004458 Process for producing crystal |
| 01/07/2010 | US20100004339 Somatostatin Receptor 1 and/or 4 Selective Agonists and Antagonists |
| 01/07/2010 | US20100004327 Novel Use of Ansamycin Antibiotics And Method of Screening Novel Angiogenesis Inhibitor |
| 01/07/2010 | US20100004314 Use of sirna to achieve down regulation of an endogenous gene in combination with the use of a sense construct to achieve expression of a polynucleotide |
| 01/07/2010 | US20100004308 Benzofuran-3-yl(indol-3-yl) Maleimides as Potent GSK3 Inhibitors |
| 01/07/2010 | US20100004306 PIGF-1 Assay and kits and components thereof |
| 01/07/2010 | US20100004286 Novel isoindolinone derivatives having inhibitory activity against t-type calcium channel and method for preparation thereof |
| 01/07/2010 | US20100004276 Vitamin receptor binding drug delivery conjugates |
| 01/07/2010 | US20100004261 Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase |
| 01/07/2010 | US20100004258 Novel Heterocyclic NF-kB Inhibitors |
| 01/07/2010 | US20100004257 Identification of Biomarkers Predictive of Dasatinib Effects in Cancer Cells |
| 01/07/2010 | US20100004250 Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer |
| 01/07/2010 | US20100004247 Combination comprising a mek inhibitor and an aurora kinase inhibitor 188 |
| 01/07/2010 | US20100004243 Pharmaceutical compounds |
| 01/07/2010 | US20100004239 Pyrrolo [3,2-C] Pyridine-4-One 2-Indolinone Protein Kinase Inhibitors |
| 01/07/2010 | US20100004234 Specific kinase inhibitors |
| 01/07/2010 | US20100004231 Inhibitors of burton's tyrosine kinase |
| 01/07/2010 | US20100004227 Compositions and methods relating to novel compounds and targets thereof |
| 01/07/2010 | US20100004220 Indenoisoquinolinone Analogs and Methods of Use Thereof |
| 01/07/2010 | US20100004217 Topical steroidal formulations |
| 01/07/2010 | US20100004208 Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors |
| 01/07/2010 | US20100004207 Inhibitors of cyclin-dependent kinases, compositions and uses related thereto |
| 01/07/2010 | US20100004196 Heparan sulfate proteoglycan composition and use thereof |
| 01/07/2010 | US20100004181 Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-(1,3,4-oxadiazol-2-yl)phenyl) pyridine-3-sulphonamide and an lhrh analogue and/or a bisphosphonate |
| 01/07/2010 | US20100004179 Targeting of ews-fli1 as anti-tumor therapy |
| 01/07/2010 | US20100004169 CCN3 peptide |
| 01/07/2010 | US20100004167 Csf3r polypeptides and uses thereof |
| 01/07/2010 | US20100004165 Novel Protein Transduction Domains and Uses Therefor |
| 01/07/2010 | US20100003682 Compositions, kits, and methods for identification, assessment, prevention and therapy of breast and ovarian cancer |
| 01/07/2010 | US20100003346 Combination methods of treating cancer |
| 01/07/2010 | US20100003324 Vinpocetine and eburn amonine derivatives for promoting bone growth |
| 01/07/2010 | US20100003323 Hydrophilic matrix containing poorly water-soluble compound and method for producing the same |
| 01/07/2010 | US20100003287 Compositions and Methods Relating to Treatment of Cancer and Infectious Diseases |
| 01/07/2010 | US20100003286 Pharmaceutical product comprising tissue of the male vegetal reproductive system |
| 01/07/2010 | US20100003280 Adjuvant compositions |